Moonshot AI Eyes Biology and Chemistry Research

The Beijing start-up's Kimi models are being tested for drug discovery and life-science workloads through a partnership with DP Technology.

Updated on Nov. 16, 2026 in Biotech

Moonshot AI Eyes Biology and Chemistry Research

Live Poll

Do you think AI will speed up new medicines reaching patients?

Moonshot AI, a Beijing-based artificial intelligence start-up that develops the Kimi models, is exploring applications in biology, chemistry and pharmaceutical research. Its director of international, Giacomo Ficari, outlined the strategy in a keynote at the Web Summit in Lisbon.

Why it matters

Coding, which drove much of the recent demand for advanced AI models, is approaching saturation in technological progress, pushing AI developers toward scientific domains. Moonshot's move mirrors similar efforts by rivals to position general-purpose models as research tools.

Kimi K3.1 Pro, paired with DP Technology's coding tool, scored highest among undisclosed model combinations in an internal biological research task evaluation. The results come from the companies' own testing, and independent verification has not been reported.

The players

Moonshot AI

A Beijing-based artificial intelligence start-up that develops the Kimi family of large language models and is expanding them into scientific research.

DP Technology

A Beijing-based AI-for-science start-up that builds research agents for biomedical and scientific workflows.

The details

Moonshot AI announced a collaboration with DP Technology, a Beijing-based AI-for-science start-up, to integrate Kimi K3.1 Pro into DP's BioMaster research agent. In a demonstration, the system analysed gene-expression data from 3,696 mouse pancreatic cells and flagged 100 candidate genes for further study.

Timeline

  1. June: A Citi survey of 50 US-based pharmaceutical R&D executives found 24 per cent expected AI to significantly improve the probability of drug success.

  2. September: Anthropic said its researchers used its Claude model to discover a new enzyme system.

  3. Earlier this month (November): A paper co-authored by Moonshot founder Yang Zhilin and Andrew Yao examined whether leading AI models could contribute to original mathematical research.

  4. Thursday (November 13, 2026): DP Technology announced its collaboration with Moonshot.

The Tech Race

Moonshot's push into life sciences follows Anthropic's September claim that its Claude model helped uncover a new enzyme system, signalling that frontier labs are racing to prove scientific value beyond software development. The move positions Kimi against US rivals competing for the same pharmaceutical research budgets.

For researchers and pharmaceutical teams, AI agents that analyse gene-expression data could shorten early-stage screening from hours to minutes. Practical adoption will depend on whether results hold up under independent validation and on how the tools integrate with existing lab workflows.

The takeaway

AI tools that compress multi-hour analyses into minutes can help teams prioritise candidates faster, but results from company-run evaluations should be checked against independent benchmarks before they influence research decisions.

Further reading

For broader context on AI reshaping lab science, see the Biotech coverage.

Source note: This article includes information reported by South China Morning Post.

Live Poll

Do you think AI will speed up new medicines reaching patients?